Brian T. Hickner

Brian T. Hickner

Auto-generated profile, based on publicly available information

Brian T. Hickner

Division of Pediatric Surgery, Michael E. DeBakey Department of Surgery, Texas Children's Hospital Surgical Oncology Program and Liver Tumor Program, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2025 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
MGMary Elizabeth Guerra
Mary Elizabeth Guerra
BHBrian T. Hickner
Brian T. Hickner
CFCelia D. Flores
Celia D. Flores
MFMary E. Fang
Mary E. Fang
CBCharlene A. Barclay
Charlene A. Barclay
JRJ. Ruben Rodriguez
J. Ruben Rodriguez

6 May 2026 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
BHBrian T. Hickner
Brian T. Hickner
AEAndres F. Espinoza
Andres F. Espinoza
PMPrakash M. Masand
Prakash M. Masand
DLDolores H. Lòpez-Terrada
Dolores H. Lòpez-Terrada
VSValeria R. Smith
Valeria R. Smith
SVSanjeev A. Vasudevan
Sanjeev A. Vasudevan

1 August 2025 in bioRxiv
Verified
Preprint
Open access
KGKathryn Glaser
Kathryn Glaser
LBLara Berklite
Lara Berklite
BHBrian T. Hickner
Brian T. Hickner
PRPriyanka Rao
Priyanka Rao
RPRoma H. Patel
Roma H. Patel
ABAlexander J. Bondoc
Alexander J. Bondoc
Hepatoblastoma (HB) is the most common pediatric liver malignancy. However, its cellular origin and molecular drivers remain poorly defined. Using single-nuclear RNA sequencing (snRNA-seq), we identified a proliferative, hepatocyte-derived tumor cell population (cycling Hep T ) enriched for Enhancer of Zeste Homolog 2 ( EZH2) expression, particularly in the aggressive embryonal subtype. Integrative genomic and transcriptomic profiling confirmed EZH2 overexpression. Disruption of the PRC2 complex was evident through mislocalization and reduced expression of SUZ12, a core component. EZH2 overexpression correlated with upregulation of mitotic regulators such as AURKB and Ki67 in human HB gene expression analysis as compared to background liver. Targeted sequencing identified variants of uncertain significance in EZH2 and SUZ12 in 11 of 11 patient tumors. Pharmacologic inhibition of EZH2 with EPZ-6438 reduced proliferation and sensitized HB cells to cisplatin through gene regulation, potentially modulating platinum accumulation both in vitro and in vivo . In summary, EZH2 promotes HB progression through epigenetic silencing and noncanonical signaling pathways. These findings support EZH2’s contribution to HB pathogenesis, therefore identifying it as a novel therapeutic target. STATEMENT OF SIGNIFICANCE: EZH2 is enriched in hepatoblastoma, suggesting its role in early tumorigenesis. Its inhibition, combined with cisplatin, produces synergistic anti-tumor effects, supporting EZH2 as both an oncogenic and therapeutic target.